Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

<p>PTEN and RB loss in HGSOC. <b>A,</b> Frequency of loss of PTEN protein expression across HRR-centric subtypes. <b>B,</b> Frequency of loss of RB protein expression across HRR-centric subtypes. <b>C,</b> Impact of RB loss on survival in patients based on H...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Robert L. Hollis (15034814) (author)
অন্যান্য লেখক: Alison M. Meynert (14956260) (author), Caroline O. Michie (15043392) (author), Tzyvia Rye (4733277) (author), Michael Churchman (15034811) (author), Amelia Hallas-Potts (15043395) (author), Ian Croy (15034823) (author), W. Glenn McCluggage (8775452) (author), Alistair R.W. Williams (15043398) (author), Clare Bartos (15034820) (author), Yasushi Iida (4097272) (author), Aikou Okamoto (14957624) (author), Brian Dougherty (108958) (author), J. Carl Barrett (11900099) (author), Ruth March (73809) (author), Athena Matakidou (15034847) (author), Patricia Roxburgh (14961464) (author), Colin A. Semple (15034853) (author), D. Paul Harkin (14873531) (author), Richard Kennedy (248483) (author), C. Simon Herrington (15034817) (author), Charlie Gourley (15034850) (author)
প্রকাশিত: 2025
বিষয়গুলি:
Cancer
Cancer Biology
Tumor Biology
Therapeutic Research and Development
Clinical Research and Trials
Gynecological Cancers
Ovarian cancer
Oncogenes & Tumor Suppressors
BRCA family
Precision Medicine
Translational Research
Tumor Microenvironment
Immune cells and the microenvironment
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
বিবরন
সংক্ষিপ্ত:<p>PTEN and RB loss in HGSOC. <b>A,</b> Frequency of loss of PTEN protein expression across HRR-centric subtypes. <b>B,</b> Frequency of loss of RB protein expression across HRR-centric subtypes. <b>C,</b> Impact of RB loss on survival in patients based on HRR status. Multivariable hazard ratio (mHR) for HRR-ab: RB loss vs. HRR-ab RB-intact = 0.50; 95% CI, 0.30–0.84; mHR for HRRwt/<i>CCNE1</i>g: RB loss vs. HRRwt/<i>CCNE1</i>g: RB-intact = 0.71; 95% CI, 0.48–1.06. <i>BRCA2</i>m, <i>BRCA2</i> mutant; <i>BRCA1</i>m, <i>BRCA1</i> mutant; <i>EMSY</i>-overxp; overexpression of <i>EMSY</i>; nBRCA-HRRm, non-<i>BRCA1</i>/<i>2</i> HRR gene mutation; <i>CCNE1</i>g, gain of <i>CCNE1</i>; HRRwt, non-<i>CCNE1</i>g HRR wild-type. HRR-ab, HRR-aberrant: <i>BRCA1</i>m, <i>BRCA2</i>m, <i>EMSY</i>-overxp, or n<i>BRCA</i>-HRRm.</p>

অনুরূপ উপাদানগুলি